𝔖 Bobbio Scriptorium
✦   LIBER   ✦

910 Ifosfamide-based salvage chemotherapy for patients with resistant germ cell tumors—our experiences

✍ Scribed by D. Donat; J. Srojkov; A. Živanović; J. Djozić; L.J. Miljković; A. Donat; N. Budišin; P. Novaković; Z. Grahovac

Book ID
116167655
Publisher
Elsevier Science
Year
1995
Tongue
English
Weight
159 KB
Volume
31
Category
Article
ISSN
0959-8049

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The role of ifosfamide plus cisplatin-ba
The role of ifosfamide plus cisplatin-based chemotherapy as salvage therapy for patients with refractory germ cell tumors
✍ Robert J. Motzer; Karen Cooper; Nancy L. Geller; Dean F. Bajorin; Ethan Dmitrovs 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 537 KB

A prospective study of four cycles of etoposide with ifosfamide and cisplatin (VIP) chemotherapy was conducted in 42 germ cell tumor (GCT) patients who were refractory to cisplatin with etoposide/vinblastine-based therapy. Forty patients were evaluable for response. Ten patients (25%) had a complete

Salvage high-dose chemotherapy in patien
Salvage high-dose chemotherapy in patients with germ cell tumors : An Italian experience with 84 patients
✍ Giovanni Rosti; Ugo De Giorgi; Roberto Salvioni; Giorgio Papiani; Loretta Sebast 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB

## Abstract ## BACKGROUND High‐dose chemotherapy (HDCT) followed by hematopoietic stem cell support (HSCS) potentially may be curative in patients with germ cell tumor (GCT) who develop recurrent tumors or who have an inadequate response after receiving standard‐dose chemotherapy. The authors repo

Serum tumor marker decline is an early p
Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy
✍ Barbara A. Murphy; Robert J. Motzer; Madhu Mazumdar; Vaia Vlamis; Jerome Nisselb 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 655 KB

Background. Serum tumor marker regression (alpha-fetoprotein [AFP] and human chorionic gonadotrophin (hCG]) was studied in patients treated with ifosfamide-based chemotherapy for cisplatin-resistant germ cell tumors (GCT) to investigate the role of marker regression as a predictor of treatment outco